Lawrence Perez has been a CMC Reviewer for new drugs with the FDA since 2015. Before that, Lawrence was a discovery chemist with Novartis Oncology. Lawrence has been active in the areas of pharmaceutical regulations and medicinal chemistry, with his most notable work being the discovery and development of the oncology drugs Farydak® and Kisqali®.